Mark Jacobson - 09 Jun 2025 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)

Signature
/s/ Mark Jacobson
Issuer symbol
AXSM
Transactions as of
09 Jun 2025
Transactions value $
-$2,560,500
Form type
4
Filing time
10 Jun 2025, 19:00:05 UTC
Previous filing
28 May 2025
Next filing
17 Sep 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jacobson Mark L. Chief Operating Officer C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK /s/ Mark Jacobson 10 Jun 2025 0001805812

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXSM Common Stock Options Exercise $201K +25K +432.3% $8.02 30.8K 09 Jun 2025 Direct F1, F2
transaction AXSM Common Stock Sale -$2.76M -25K -81.21% $110.44 5.78K 09 Jun 2025 Direct F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXSM Stock Option (Right to Buy) Options Exercise $0 -25K -100% $0.00 0 09 Jun 2025 Common Stock 25K $8.02 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months.
F2 Such transaction was pursuant to a pre-approved 10b5-1 plan.
F3 Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
F4 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $108.27 and $112.24.